OncoMatch/Clinical Trials/NCT07137494
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Is NCT07137494 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies MB-CART19.1 Cellular Therapy for primary central nervous system (cns) lymphoma.
Treatment: MB-CART19.1 Cellular Therapy — This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Primary Central Nervous System Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression
If the most recent CSF or brain tissue sample demonstrates absence of CD19 expression [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: methotrexate-based CNS-directed therapy — CNS lymphoma
All relapsed/refractory patients need to have received at least one prior CNS-directed methotrexate-based therapy
Cannot have received: CD19-targeted CAR T cell therapy for systemic lymphoma
Prior treatment of systemic lymphoma with CD19-targeted CAR T cells
Lab requirements
Kidney function
Creatinine Clearance ≥ 40 ml/min/m2
Liver function
direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN)
Cardiac function
Impaired cardiac function (LVEF <40%) as assessed by most recent ECHO in the last 1 year. NYHA stage III or IV congestive heart failure, myocardial infarction ≤6 months prior to enrollment, history of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment
Creatinine Clearance ≥ 40 ml/min/m2, direct bilirubin ≤2.0 mg/100 ml, AST and ALT ≤3.0x upper limit of normal (ULN). Impaired cardiac function (LVEF <40%) as assessed by most recent ECHO in the last 1 year. Patients with following cardiac conditions will be excluded: NYHA stage III or IV congestive heart failure, myocardial infarction ≤6 months prior to enrollment, history of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration ≤6 months prior to enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering at Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07137494 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD19-targeted CAR T cell therapy for systemic lymphoma disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify